Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Oculis Holding AGNASDAQ: OCS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of CHF 28.95M (cash outflow) fell 12.8% year over year, behind the -8.3% change in trailing-twelve-month net income. Sequentially, it rose 24.1% from the prior quarter. Over 3 fiscal years it compounded at +34.7% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -CHF 74.81M (-20.8%) for the fiscal year ending Dec 2026, a slowdown from the +10.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 28.95M+24.1% QoQ
Last fiscal yearDec 2025
-CHF 94.51M+10.0% YoY
LTMMar 2026
-CHF 94.54M-8.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.8%-6.1%+6.7 pp
1 year+10.0%-20.8%-30.8 pp
3-year CAGR+34.7%+0.7%-34.0 pp
5-year CAGR-39.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CHF · from the cash flow

Latest · FY2025
(94.51M) CHF
Year-over-year change
-10.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.3% is the 3rd highest of 6, against a peer median of -31.0%.
  • Net income amounts to 18758.0% of revenue for OCS, versus a peer median of 2062.4%.
OCS Competitors
Net Income for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCULOcular Therapeutix, Inc.LTM Mar 2026$290.5M USD+50.7%+55.3%558.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$271.6M USD+85.0%+31.4%3566.6%
OCSOculis Holding AGLTM Mar 2026CHF 94.54M CHF-8.3%+34.7%18758.0%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M USD-388.6%-1.9%18297.5%
HROWHarrow Health, Inc.LTM Mar 2026$14.96M USD-31.0%-28.5%5.6%
OKYOOKYO Pharma LimitedFY2025$7.97M USD-52.6%+8.6%—
Peer median (excluding OCS) —-31.0%+8.6%2062.4%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.52M)(38.64M)(88.7M)(85.94M)(94.51M)
Depreciation & Amortization235K299K287K406K546K
Deferred Income Tax00000
Stock-Based Compensation328K804K3.61M9.78M16.04M
Change in Working Capital(791K)6M(12.99M)14.16M(70.67K)
Accounts Receivables233K(152K)36K247K1.9M
Inventory00000
Accounts Payables30K3.04M3.73M(1.71M)(1.86M)
Other Working Capital(1.05M)3.11M(16.76M)15.62M(106.97K)
Other Non-Cash Items4.93M6.47M43.95M14.09M15.77M
Operating Cash Flow(13.83M)(25.07M)(53.85M)(47.5M)(62.22M)
Capital Expenditures(28K)(3.55M)(48K)(230K)(287.47K)
Acquisitions (Net)00000
Purchases of Investments00(54.16M)(17.33M)(58.05M)
Sales of Investments00000
Other Investing Activities0(3.48M)000
Investing Cash Flow(28K)(3.55M)(54.21M)(17.56M)(59.38M)
Debt Repayment(98K)(159K)(158K)(274K)(373K)
Common Stock Issued00135.62M53.54M178.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(804K)(157K)(5.79M)763K16.77K
Financing Cash Flow55.19M1.71M129.67M54.03M178.6M
Effect of Forex Changes(16K)418K(3.08M)407K174.39K
Net Change in Cash41.33M(26.49M)18.54M(10.62M)57.17M
Free Cash Flow(13.85M)(28.62M)(53.89M)(47.73M)(62.51M)

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.